Neuronetics Competitors

Cerus (NASDAQ:CERS) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cerus and Neuronetics, as provided by MarketBeat.

Cerus presently has a consensus price target of $7.8333, indicating a potential upside of 24.73%. Neuronetics has a consensus price target of $19.25, indicating a potential upside of 25.08%. Given Neuronetics' higher possible upside, analysts plainly believe Neuronetics is more favorable than Cerus.

Profitability

This table compares Cerus and Neuronetics' net margins, return on equity and return on assets.

Volatility & Risk

Cerus has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500.

Insider and Institutional Ownership

82.1% of Cerus shares are owned by institutional investors. Comparatively, 63.8% of Neuronetics shares are owned by institutional investors. 6.5% of Cerus shares are owned by company insiders. Comparatively, 6.0% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cerus and Neuronetics' gross revenue, earnings per share and valuation.

Neuronetics has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Summary

Cerus beats Neuronetics on 7 of the 13 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and LeMaitre Vascular, as reported by MarketBeat.

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. LeMaitre Vascular has a consensus target price of $36.1667, indicating a potential downside of 28.78%. Given Neuronetics' stronger consensus rating and higher possible upside, research analysts clearly believe Neuronetics is more favorable than LeMaitre Vascular.

Profitability

This table compares Neuronetics and LeMaitre Vascular's net margins, return on equity and return on assets.

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neuronetics and LeMaitre Vascular's revenue, earnings per share and valuation.

LeMaitre Vascular has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Summary

LeMaitre Vascular beats Neuronetics on 10 of the 14 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and OrthoPediatrics, as reported by MarketBeat.

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. OrthoPediatrics has a consensus target price of $54.25, indicating a potential upside of 6.21%. Given Neuronetics' higher possible upside, research analysts clearly believe Neuronetics is more favorable than OrthoPediatrics.

Profitability

This table compares Neuronetics and OrthoPediatrics' net margins, return on equity and return on assets.

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. Comparatively, 71.7% of OrthoPediatrics shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neuronetics and OrthoPediatrics' revenue, earnings per share and valuation.

OrthoPediatrics has higher revenue and earnings than Neuronetics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Summary

OrthoPediatrics beats Neuronetics on 9 of the 13 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and CryoLife (NYSE:CRY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and CryoLife, as reported by MarketBeat.

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. CryoLife has a consensus target price of $28.3333, indicating a potential upside of 11.46%. Given Neuronetics' higher possible upside, research analysts clearly believe Neuronetics is more favorable than CryoLife.

Profitability

This table compares Neuronetics and CryoLife's net margins, return on equity and return on assets.

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. Comparatively, 80.9% of CryoLife shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 4.7% of CryoLife shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neuronetics and CryoLife's revenue, earnings per share and valuation.

CryoLife has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Summary

CryoLife beats Neuronetics on 7 of the 13 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and SI-BONE, as reported by MarketBeat.

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. SI-BONE has a consensus target price of $30.60, indicating a potential upside of 0.69%. Given Neuronetics' higher possible upside, research analysts clearly believe Neuronetics is more favorable than SI-BONE.

Profitability

This table compares Neuronetics and SI-BONE's net margins, return on equity and return on assets.

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. Comparatively, 65.3% of SI-BONE shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 15.5% of SI-BONE shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neuronetics and SI-BONE's revenue, earnings per share and valuation.

Neuronetics has higher earnings, but lower revenue than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Summary

SI-BONE beats Neuronetics on 7 of the 12 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Neuronetics and Tactile Systems Technology's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and Tactile Systems Technology, as reported by MarketBeat.

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. Tactile Systems Technology has a consensus target price of $61.75, indicating a potential upside of 26.87%. Given Tactile Systems Technology's higher possible upside, analysts clearly believe Tactile Systems Technology is more favorable than Neuronetics.

Valuation & Earnings

This table compares Neuronetics and Tactile Systems Technology's revenue, earnings per share and valuation.

Tactile Systems Technology has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 5.3% of Tactile Systems Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Tactile Systems Technology beats Neuronetics on 8 of the 14 factors compared between the two stocks.